Skip to main content

Table 1 Expression of MCT1, MCT4 and CD147 in EC tumours and their correlation with clinico–pathological characteristics

From: Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer

   MCT1 (N = 89) MCT4 (N = 87) CD147 (N = 87)
  N = 90 (%) Low (<200)
N = 48 (53.9%)
High (≥200)
N = 41 (46.1%)
p Low (<200)
N = 59 (67.8%)
High (≥200)
N = 28 (32.2%)
p Low (<200)
N = 31 (35.6%)
High (≥200)
N = 56 (64.4%)
p
Age of Onset (Median, IQR years) 67 (57.7–74) 69 (58.2–74.7) 67 (56–73) 0.917 67 (56–74) 69.5 (61.5–75.2) 0.760 67 (61–73) 68 (56–75) 0.836
BMI (Median) 29.4 (26–37.8) 29 (26.1–35.1) 39 (26–39.5) 0.764 30.7 (26–39.4) 28 (26.2–34.9) 0.596 28.2 (23.2–34.9) 30.2 (26.3–39.5) 0.557
Diabetic, N (%)     0.094    0.949    0.678
 Yes (0) 71 (78.9%) 41 (58.6%) 29 (41.4%)   46 (67.6%) 22 (32.4%)   25 (36.8%) 43 (63.2%)  
 No (1) 19 (21.1%) 7 (36.8%) 12 (63.2%)   13 (68.4%) 6 (31.6%)   6 (31.6%) 13 (68.4%)  
Grade, N (%)     0.218    0.313    0.737
 I/II 42 (46.7%) 25 (60.9%) 16 (39.1%)   30 (73.1%) 11 (26.9%)   15 (37.5%) 25 (62.5%)  
 III 48 (53.3%) 23 (47.9%) 25 (52.1%)   29 (63.1%) 17 (36.9%)   16 (34.1%) 31 (65.9%)  
Histological Type, N (%)     0.614    0.409    0.988
 Endometrioid (1) 47 (52.2%) 26 (56.5%) 20 (43.5%)   26 (56.5%) 20 (43.5%)   16 (35.6%) 29 (64.4%)  
aNon–endometrioid (2) 43 (47.8%) 22 (51.2%) 21 (48.8%)   22 (51.2%) 21 (48.8%)   15 (35.7%) 27 (64.3%)  
FIGO 2009 Stage, N (%)     0.752    0.988    0.026
 I 58 (64.4%) 31 (54.4%) 26 (45.6%)   37 (66.1%) 19 (33.9%)   25 (44.6%) 31 (55.4%)  
 II 11 (12.2%) 5 (45.5%) 6 (54.5%)   9 (81.8% 2 (18.2%)   2 (18.2%) 9 (81.8%)  
 III 19 (21.1%) 10 (52.6%) 9 (47.4%)   12 (66.7%) 6 (33.3%)   4 (22.2%) 14 (77.8%)  
 IV 2 (2.2%) 2 (100%) 0 (0%)   1 (50.0%) 1 (50.0%)   0 (0%) 2 (100%)  
Tumour Size, N (%)     0.234    0.866    0.117
 Less than 2 cm (1) 9 (10.0%) 5 (55.6%) 4 (44.4%)   7 (77.8%) 2 (22.2%)   4 (50.0%) 4 (50.0%)  
 2–5 cm (2) 46 (51.1%) 28 (62.2%) 17 (37.8%)   32 (71.1%) 13 (28.9%)   19 (43.2%) 25 (56.8%)  
 Bigger than 5 cm (3) 11 (26.7%) 10 (41.7%) 14 (58.3%)   16 (72.7%) 6 (27.3%)   6 (25.0%) 18 (75.0%)  
 Missing 24 (26.7%)          
LVSI, N (%)     0.928    0.692    0.948
 No (0) 50 (55.6%) 26 (53.1%) 23 (46.6%)   33 (67.3%) 16 (32.7%)   17 (35.4%) 31 (64.6%)  
 Yes (1) 37 (41.1%) 20 (54.1%) 17 (45.9%)   25 (71.4%) 10 (28.6%)   13 (36.1%) 23 (63.9%)  
 Missing 3 (3.3%)          
Depth of Myometrial Invasion, N (%)     0.680    0.203    0.512
 Less than (<) 50% 50 (55.6%) 26 (52.0%) 24 (48.0%)   36 (73.5%) 13 (26.5%)   16 (32.7%) 33 (67.3%)  
 More than or equal to (≥) 50% 40 (44.4%) 22 (56.4%) 17 (43.6%)   23 (60.5%) 15 (39.5%)   15 (39.5%) 23 (60.5%)  
  1. aNon-EEC tumours are composed of tumours with carcinosarcoma, mixed, clear cell, serous and undifferentiated histology
\